Capital Analysts LLC Buys 5,222 Shares of Becton, Dickinson and Company $BDX

Capital Analysts LLC increased its holdings in shares of Becton, Dickinson and Company (NYSE:BDX) by 8.2% during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 69,014 shares of the medical instruments supplier’s stock after acquiring an additional 5,222 shares during the quarter. Capital Analysts LLC’s holdings in Becton, Dickinson and Company were worth $13,394,000 as of its most recent SEC filing.

A number of other institutional investors have also made changes to their positions in BDX. Wellington Management Group LLP increased its holdings in shares of Becton, Dickinson and Company by 9,056.3% during the 3rd quarter. Wellington Management Group LLP now owns 5,232,086 shares of the medical instruments supplier’s stock worth $979,290,000 after acquiring an additional 5,174,944 shares during the last quarter. Vanguard Group Inc. increased its holdings in shares of Becton, Dickinson and Company by 13.0% during the 4th quarter. Vanguard Group Inc. now owns 36,678,939 shares of the medical instruments supplier’s stock worth $7,118,282,000 after acquiring an additional 4,223,149 shares during the last quarter. Northwestern Mutual Wealth Management Co. increased its holdings in shares of Becton, Dickinson and Company by 23,219.2% during the 4th quarter. Northwestern Mutual Wealth Management Co. now owns 4,155,709 shares of the medical instruments supplier’s stock worth $769,397,000 after acquiring an additional 4,137,888 shares during the last quarter. Norges Bank acquired a new position in shares of Becton, Dickinson and Company during the 4th quarter worth approximately $734,321,000. Finally, First Eagle Investment Management LLC increased its holdings in shares of Becton, Dickinson and Company by 16.5% during the 4th quarter. First Eagle Investment Management LLC now owns 11,646,000 shares of the medical instruments supplier’s stock worth $2,260,139,000 after acquiring an additional 1,651,592 shares during the last quarter. 86.97% of the stock is owned by institutional investors and hedge funds.

Analysts Set New Price Targets

A number of research firms recently weighed in on BDX. Evercore boosted their target price on Becton, Dickinson and Company from $180.00 to $190.00 in a report on Thursday, May 7th. Wells Fargo & Company boosted their target price on Becton, Dickinson and Company from $157.00 to $161.00 and gave the stock an “equal weight” rating in a report on Friday, May 8th. Royal Bank Of Canada set a $175.00 target price on Becton, Dickinson and Company in a report on Tuesday, April 14th. Barclays boosted their target price on Becton, Dickinson and Company from $202.00 to $204.00 and gave the stock an “overweight” rating in a report on Monday, May 11th. Finally, Weiss Ratings lowered Becton, Dickinson and Company from a “hold (c-)” rating to a “sell (d+)” rating in a report on Monday, May 11th. Seven equities research analysts have rated the stock with a Buy rating, eight have given a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat, the stock currently has a consensus rating of “Hold” and a consensus target price of $183.64.

Insider Buying and Selling

In other Becton, Dickinson and Company news, CEO Thomas E. Polen, Jr. sold 2,764 shares of the company’s stock in a transaction on Monday, June 1st. The stock was sold at an average price of $146.35, for a total value of $404,511.40. Following the transaction, the chief executive officer directly owned 110,163 shares of the company’s stock, valued at $16,122,355.05. This represents a 2.45% decrease in their position. The sale was disclosed in a filing with the SEC, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last quarter, insiders sold 2,913 shares of company stock valued at $426,806. Corporate insiders own 0.40% of the company’s stock.

Becton, Dickinson and Company Stock Performance

Shares of NYSE BDX opened at $152.05 on Wednesday. The company has a debt-to-equity ratio of 0.62, a current ratio of 0.94 and a quick ratio of 0.55. The stock’s fifty day moving average price is $150.53 and its two-hundred day moving average price is $174.85. Becton, Dickinson and Company has a one year low of $127.59 and a one year high of $187.35. The firm has a market cap of $41.90 billion, a price-to-earnings ratio of 38.49, a P/E/G ratio of 10.62 and a beta of 0.22.

Becton, Dickinson and Company (NYSE:BDX) last issued its quarterly earnings data on Thursday, May 7th. The medical instruments supplier reported $2.90 EPS for the quarter, beating analysts’ consensus estimates of $2.77 by $0.13. Becton, Dickinson and Company had a return on equity of 15.37% and a net margin of 5.33%.The firm had revenue of $4.71 billion for the quarter, compared to analyst estimates of $4.67 billion. During the same period in the prior year, the firm posted $3.35 EPS. The company’s revenue for the quarter was up 5.2% on a year-over-year basis. Becton, Dickinson and Company has set its FY 2026 guidance at 12.520-12.720 EPS. On average, equities analysts forecast that Becton, Dickinson and Company will post 12.61 EPS for the current year.

Becton, Dickinson and Company Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Tuesday, June 30th. Shareholders of record on Tuesday, June 9th will be issued a $1.05 dividend. This represents a $4.20 dividend on an annualized basis and a yield of 2.8%. The ex-dividend date of this dividend is Tuesday, June 9th. Becton, Dickinson and Company’s dividend payout ratio is currently 106.33%.

Becton, Dickinson and Company Company Profile

Becton, Dickinson and Company (BDX) is a global medical technology company that develops, manufactures and sells a broad range of medical devices, instrument systems and reagents. BD’s products are used by healthcare institutions, clinical laboratories, life science researchers and the pharmaceutical industry to enable safe, effective delivery of care, specimen collection and diagnostic testing. The company’s operations span multiple business areas focused on medical devices, life sciences research tools and interventional technologies.

BD’s product portfolio includes single-use medical devices such as syringes, needles, needlesafety and injection systems, infusion therapy and medication management solutions, as well as vascular access, urology and oncology devices acquired through its interventional business.